

# Introduction and overall state of play of the Accreditation and Designation Programme


Simon Oberst, Director of Quality and Accreditation

Jean-Benoît Burrion, Chair, A&D Board

14<sup>th</sup> June 2023 0830, Paris Oncology Days



# State of play



35 accredited CCCs

18 accredited CCs

17 centres newly in the process

=70 centres in all



# List of centres in the process in 2023-2024




1. National Cancer Institute, Vilnius, **Lithuania**
2. Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago, **Chile**
3. Mediterranean Institute of Oncology, Catania, **Italy**
4. IRCCS Ospedale Policlinico San Martino, Genova, **Italy**
5. Centre Henri Becquerel, Rouen, **France**
6. Eugène Marquis Cancer Centre, Rennes, **France**
7. IPO Lisbon, Lisbon, **Portugal**
8. IRCCS Istituto Clinico Humanitas, Milan, **Italy**
9. Galway University Hospital, Galway, **Ireland**
10. Ospedale San Raffaele (OSR), Milan, **Italy**
11. Centre Léon Bérard, Lyon, **France**
12. Uppsala University Hospital, Uppsala, **Sweden**
13. AZ Groeninge, Kortrijk, **Belgium**
14. Cancer Institute AP-HP. Nord – Université Paris Cité, Paris, **France**
15. Linköping University Hospital cancer center, Linköping, **Sweden**
16. Anadolu Medical Center, Anadolu, **Turkey**
17. National Institute Oncology, Budapest, **Hungary**
18. General Oncology Hospital of Athens “Saint Savvas”, Athens, **Greece**
19. Centre Jean Perrin, Clermont-Ferrand, **France**
20. Fundación Instituto Valenciano de Oncología IVO, Valencia, **Spain**
21. Cork University Hospital/University College Cork, **Dublin**
22. Leuven Cancer Institute, Leuven, **Belgium**
23. ASST Spedali Civili di Brescia:

Pilot of Network accreditation:  
Oncozon – South Netherlands



- The last few years have seen big growth in France, Sweden and Finland
- Now we see considerable interest in Spain, Ireland, Denmark, Czech republic, Netherlands, Italy, Bulgaria, Slovakia, and others...
- We need to think beyond Europe – e.g. South America



## In the A&D Programme: 94 active Auditors

- 10 Directors
- 21 Nurses / Nurse background
- 20 Quality Managers
- 25 Physicians
- 16 Research background
- 2 other (pharmacy, psychologist)

Therefore – emphasis on training and refreshment about our processes

➤ We will be recruiting more auditors for a March 2024 training



- JRC / European Commission Initiative in Breast Cancer (ended):
  - OECD took part in a pilot
  - OECD accreditation approach is more realistic
  
- DG Reform Latvia (ended): Advising on a roadmap to create a Comprehensive Cancer Infrastructure in Latvia
  - 3 consultants
  - Major data gathering
  - 3 2-day site visits
  - Report and recommendations



- CrANE (running): Preparations to create an EU Network of Comprehensive Cancer Centres (CCCs)
  - Full talk tomorrow
  - Wide definition of CCCs
  - The OEI accredited network will continue to run in parallel, and must offer added value
  - OEI-accreditation will be pre-recognised for admission of CCCs
  - OEI is helping to craft research and innovation standards which will be aligned with OEI's own
- CCI4EU (OEI coordinating): federating 55 partners: Capacity Building in Comprehensive Cancer Infrastructures (CCIs)
  - Full talk tomorrow
  - Mobilisation of around 100 subject experts
  - 9 CCIs will be chosen for a 'Deep Dive' tailored intervention
  - 3 years; €10million; proof of concept
  - Focus on research and innovation in cancer
  - This will be resource-intensive for OEI



*Stockholm*

*Brussels EU Parliament*

*Madrid*

*Pamplona*

*Gothenburg*

*Bratislava*

*Luxembourg*

*Sofia*

*Dublin*

*East Netherlands*

*Geneva*

*Heidelberg*

*Brussels*

*Rome*

*Tirana*



THE LANCET  
Oncology

Submit Article

THE LANCET ONCOLOGY COMMISSION | VOLUME 24, ISSUE 1, E11-E56, JANUARY 2023

## European Groundshot—addressing Europe's cancer research challenges: a *Lancet Oncology* Commission

Prof Mark Lawler, PhD • Lynne Davies, PhD • Simon Oberst, FCA • Kathy Oliver, BA •

Prof Alexander Eggermont, MD • Anna Schmutz, BSc • et al. [Show all authors](#)

Published: November 15, 2022 • DOI: [https://doi.org/10.1016/S1470-2045\(22\)00540-X](https://doi.org/10.1016/S1470-2045(22)00540-X) • [Check for updates](#)

One of the most important summary papers on Cancer Research in Europe over the last 10 years – OEI contributed data and comment on CCCs



ACTA ONCOLOGICA  
2023, VOL. 62, NO. 1, 15–24  
<https://doi.org/10.1080/0284186X.2023.2170275>



ORIGINAL ARTICLE

 OPEN ACCESS 

Addressing Comprehensive Cancer Networks  
– how to evaluate their effectiveness (and  
introducing OEI network standards)

## Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OEI comprehensive cancer network standards

Anke Wind<sup>a</sup>, Simon Oberst<sup>b</sup>, Willien Westerhuis<sup>b,c</sup>, Harriet Blaauwgeers<sup>b,c</sup>, Gunnar Sæter<sup>b,d</sup>, Paolo de Paoli<sup>b,e</sup>, Péter Nagy<sup>b,f</sup>, Jean-Benoit Burrion<sup>b,g</sup>, Eva Jolly<sup>b,h</sup>, József Lovey<sup>b,f</sup> and Wim van Harten<sup>a,b,i</sup>

<sup>a</sup>Rijnstate Hospital, Arnhem, The Netherlands; <sup>b</sup>Accreditation and Designation, Organisation of European Cancer Institutes, Brussels, Belgium; <sup>c</sup>The Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; <sup>d</sup>Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; <sup>e</sup>Alliance Against Cancer, Rome, Italy; <sup>f</sup>National Institute of Oncology, Budapest, Hungary; <sup>g</sup>Institut Jules Bordet, Brussels, Belgium; <sup>h</sup>Netherlands Cancer Institute, Amsterdam, The Netherlands; <sup>i</sup>Theme Cancer, Karolinska University Hospital, Stockholm, Sweden

- ❖ There is very little in the literature on how to evaluate the effectiveness of cancer networks
- ❖ The new OEI network standards set a new benchmark for accreditation



# Planning the future



1. Expanding the OEI quality and A&D community (within Europe, and beyond)
  - ✓ Our first peer review in South America
2. Creating more of a sense of community: spreading excellent practices; offering benchmarking; proposing support
  - ✓ Second round of excellent practices next year
3. Consolidating and improving the A&D programme
  - ✓ 4<sup>th</sup> review of our standards 2023-25 – even smarter! (OEI members will be fully involved in identifying gaps and getting rid of redundancies)
  - ✓ Concentrating on our added value to centres
  - ✓ Making certain processes more clear
4. Enlarging the A&D Board – more members and patient expert
5. Improving our webpages to be more engaging and interactive



- ❖ In the Standards Revision process we want to gain feedback from you, our members
- ❖ In the light of various EU initiatives, including Crane, we want to develop and improve what is distinctive about our quality and accreditation programme:
  - We believe in peer reviews, not technical audits
  - Our auditors are all professionals in Cancer Centres from day to day
  - Our programme is voluntary, not regulatory
  - We are enabling, not controlling
  - We can order our affairs and programme as our member experts and scientific findings demonstrate are best standards and practices
  - We want to be an effective community of practice where we enable each centre to improve, develop and learn from each other.



Thank you for your attention

